Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VVOS vs TPST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TPST Captures Overall Composite Edge (39.2 SELL vs 36.4 SELL), While VVOS Leads 3–2 on Growth & Valuation Pillars

TPST Overall Winner 6-Pillar Tally: VVOS 3 – 2 TPST (1 Tie) Matrix Metrics: VVOS 1 – 5 TPST

As of Nov 20, 2026, Tempest Therapeutics, Inc. (TPST) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (39.2/100 SELL vs. 36.4/100 SELL) after splitting the core matrix 5–1 (led by Profitability & Quality, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. VVOS trades at $0.05 (N/M Forward P/E, -107.9% operating margin) versus TPST at $0.29 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: TPST earns the overall head-to-head edge with a stronger Unified Composite Score (39.2/100 SELL vs. VVOS 36.4/100 SELL) and 0.77β · 85% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although TPST compares more favorably head-to-head, both VVOS (36.4/100 SELL) and TPST (39.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile TPST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VVOS vs TPST
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13
TPST NASDAQ Head-to-Head Winner
Tempest Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.29
-6.18% 1D
Market Cap $6.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.77β · 85% Vol
Unified Composite Score
39.2 / 100 SELL
Tech 25.0 Fund 44.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 20
RSI-14: 20.5 · SMA20: $0.41 · SMA50: $0.63

6-Pillar Scorecard Institutional Category Breakdown (VVOS 3 – 2 TPST)

Columns: Metric · VVOS · TPST
1. Valuation Multiples VVOS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.1x N/M
2. Growth & Scale VVOS
Revenue Growth (YoY) +34.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $21M N/A
Market Cap $1.9M $6.1M
3. Profitability & Quality TPST
Gross Margin 61.9% N/A
Operating Margin -107.9% 0.0%
Net Profit Margin -121.8% 0.0%
Return on Equity (ROE) -8585.3% -1797.6%
4. Balance Sheet & Cash Flow VVOS
Cash Generation (TTM) -$21M EBITDA N/A
Cash Flow Margin -99.3% EBITDA Mgn N/A
Net Cash / Leverage -8585.3% ROE $6.8M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TPST
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VVOS (1) vs TPST (5)
Institutional Metric VVOS TPST Criterion Row Edge
Market Capitalization
Scale
$1.9M $6.1M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+34.9% +0.0% Higher Growth VVOS
Operating Margin (TTM)
Profitability
-107.9% 0.0% Higher Margin TPST
Net Profit Margin
Profitability
-121.8% 0.0% Higher Margin TPST
Return on Equity (ROE)
Capital Efficiency
-8585.3% -1797.6% Higher ROE TPST
52-Week Range Position
Momentum
0% ($0–$3) 0% ($0–$9) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.70β · 111% Vol 0.77β · 85% Vol Lower Realized Risk TPST
Unified Institutional Score
Composite Signal
36.4 / 100 (SELL) 39.2 / 100 (SELL) Higher Composite TPST
Trailing 12M Revenue (USD)
Operating Scale
$21M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M EBITDA (-8585.3% ROE) N/A ($6.8M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TPST +14.2 pp
VVOS: -59.25% · TPST: -45.05%
3M Horizon TPST +6.58 pp
VVOS: -80.49% · TPST: -73.91%
6M Horizon TPST +6.58 pp
VVOS: -91.15% · TPST: -84.57%
1Y Horizon TPST +3.75 pp
VVOS: -97.71% · TPST: -93.96%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VVOS Revenue TPST Revenue VVOS Op. Margin TPST Op. Margin Margin Leader
FY2017 N/A $0M N/A -28585.1% TPST
FY2019 $10M N/A -92.8% N/A VVOS
FY2020 $10M N/A -92.1% N/A VVOS
FY2021 $20M N/A -120.7% N/A VVOS
FY2022 $20M N/A -156.2% N/A VVOS
FY2023 $10M N/A -125.3% N/A VVOS
FY2024 $20M N/A -74.3% N/A VVOS
FY2025 $20M N/A -114.1% N/A VVOS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TPST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TPST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TPST Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VVOS vs TPST Key Questions & Quantitative Answers

As of Nov 20, 2026, Tempest Therapeutics, Inc. (TPST) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (39.2/100 SELL vs. 36.4/100 SELL) after splitting the core matrix 5–1 (led by Profitability & Quality, Options & Positioning), while VVOS wins 3–2 across the 6-pillar growth and valuation breakdown. VVOS trades at $0.05 (N/M Forward P/E, -107.9% operating margin) versus TPST at $0.29 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: TPST earns the overall head-to-head edge with a stronger Unified Composite Score (39.2/100 SELL vs. VVOS 36.4/100 SELL) and 0.77β · 85% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although TPST compares more favorably head-to-head, both VVOS (36.4/100 SELL) and TPST (39.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VVOS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9); meanwhile TPST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VVOS leads the Growth & Scale pillar: VVOS posts +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin), compared with TPST at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), VVOS cumulative revenue shifted +100.0% while TPST shifted N/A. In operating R&D and SG&A reinvestment, VVOS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TPST.

VVOS screens cheaper on headline valuation multiples. VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin), whereas TPST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VVOS (-8585.3% ROE) versus TPST (-1797.6% ROE) capital efficiency.

In options market volatility and institutional positioning, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk). By comparison, TPST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.77β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.